ARDS - Aridis Pharmaceuticals Inc Stock Price, Fair Value and News

0.06USD0.00 (0.00%)Market Closed

Market Summary

USD0.060.00

Market Closed

0.00%

ARDS Stock Price

View Fullscreen

ARDS RSI Chart

ARDS Valuation

Market Cap

3.1M

Price/Earnings (Trailing)

-2.73

Price/Sales (Trailing)

0.14

Price/Free Cashflow

-0.17

ARDS Price/Sales (Trailing)

ARDS Profitability

Return on Equity

-0.67%

Return on Assets

-17.48%

Free Cashflow Yield

-573.2%

ARDS Fundamentals

ARDS Revenue

Revenue (TTM)

21.5M

Rev. Growth (Yr)

4.51%

Rev. Growth (Qtr)

-97.88%

ARDS Earnings

Earnings (TTM)

-1.1M

Earnings Growth (Yr)

98.99%

Earnings Growth (Qtr)

-100.68%

Breaking Down ARDS Revenue

Last 30 days

-14.3%

Last 90 days

-14.3%

Trailing 12 Months

-70.6%

How does ARDS drawdown profile look like?

ARDS Financial Health

Current Ratio

0.24

ARDS Investor Care

Shares Dilution (1Y)

151.81%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	3.0M	21.4M	21.5M	0
2022	4.4M	4.6M	1.9M	0
2021	0	2.0M	3.1M	4.1M
2020	0	1.0M	1.0M	1.0M
2019	3.5M	3.4M	2.4M	1.0M
2018	1.3M	1.8M	2.3M	2.8M
2017	0	0	0	860.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aridis Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jun 05, 2023	hamilton john f	acquired	-	-	5,000	-
Jun 05, 2023	kurland fred	acquired	-	-	4,000	cfo
Jun 05, 2023	windham-bannister susan richards	acquired	-	-	5,000	-
Jun 05, 2023	patzer eric	acquired	-	-	12,000	executive chairman
Jun 05, 2023	truong vu	acquired	-	-	15,000	ceo and director
Jun 05, 2023	jafri hasan	acquired	-	-	10,000	chief medical officer
Sep 07, 2021	jafri hasan	bought	8,659	4.14139	2,091	chief medical officer
Sep 03, 2021	jafri hasan	bought	12,487	4.15	3,009	chief medical officer
Jul 27, 2021	hamilton john f	bought	9,740	4.87	2,000	-
Jul 27, 2021	patzer eric	bought	25,047	4.84	5,175	-

Which funds bought or sold ARDS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 09, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	sold off	-100	-10.00	-	-%
Jan 08, 2024	Bartlett & Co. LLC	new	-	-	-	-%
Sep 09, 2022	B. Riley Wealth Management, Inc.	new	-	11.00	11.00	-%
Jul 12, 2022	Minot Wealth Management LLC	unchanged	-	-33,000	55,000	0.01%

Are Funds Buying or Selling ARDS?

Are funds buying ARDS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ARDS

No. of Funds

Unveiling Aridis Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	9.99%	4,626,190	SC 13G/A
Feb 13, 2024	lind global fund ii lp	0%	0	SC 13G/A
Mar 20, 2023	lind global fund ii lp	8.3%	3e+06	SC 13G
Feb 14, 2023	armistice capital, llc	9.99%	2,997,111	SC 13G
Feb 10, 2023	astrazeneca plc	3.4%	884,956	SC 13G/A
Dec 19, 2022	cystic fibrosis foundation	19.9%	5,168,732	SC 13G
Feb 14, 2022	francis capital management, llc	1.0%	142,838	SC 13G/A
Jul 27, 2021	astrazeneca plc	7.3%	884,956	SC 13G
Apr 01, 2021	francis capital management, llc	6.1%	676,859	SC 13G

Recent SEC filings of Aridis Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Aridis Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.57	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Aridis Pharmaceuticals Inc News

Latest updates

Aridis Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	-97.9%	417	19,647	1,082	399	292	1,187	-	3,141	1,571	-	-	1,000	-	-	-	1,022	1,390	1,022	22.00	322	222
Costs and Expenses	-	-	-	-	7,811	8,029	8,611	9,539	21,541	6,267	5,823	5,792	5,230	5,689	7,395	8,266	8,759	6,968	7,642	4,572	7,692	-
Operating Expenses	-78.5%	1,286	5,978	7,345	7,811	8,029	8,611	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-15.2%	1,111	1,310	1,814	1,693	1,681	2,161	1,973	1,699	1,694	1,592	1,631	1,583	1,388	1,384	1,613	1,641	1,386	735	687	1,066	-
R&D Expenses	-96.3%	175	4,668	5,531	6,118	6,348	6,450	7,566	19,842	4,573	4,231	4,161	3,647	4,301	6,011	6,653	7,118	5,582	6,907	3,885	6,626	-
Income Taxes	-100.0%	-	7.00	1.00	3.00	-	-	-	-	-	-	-	-	-	-	-	2.00	1.00	-	-	-	-
Net Income	-100.7%	-83.00	12,144	-6,816	-8,239	-7,979	-7,766	-8,810	-21,002	-5,490	-5,823	-5,786	-4,220	-5,648	-7,587	-8,383	-8,063	-5,438	-7,909	-1,424	-7,334	-
Net Income Margin	98.9%	-0.05*	-4.95*	-15.67*	-17.46*	-9.86*	-9.85*	-10.22*	-11.72*	-9.36*	-22.33*	-22.04*	-23.70*	-	-	-	-	-	-	-	-	-
Free Cashflow	77.6%	-983	-4,392	-4,051	-4,265	-6,151	-10,187	-3,686	-8,707	-6,731	-5,429	-5,600	-5,227	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	0.8%	7.00	6.00	9.00	15.00	12.00	17.00	24.00	27.00	26.00	11.00	18.00	15.00	12.00	18.00	22.00	28.00	34.00	16.00	23.00	32.00	39.00
Current Assets	5.8%	4.00	4.00	7.00	12.00	9.00	13.00	20.00	24.00	24.00	9.00	15.00	13.00	10.00	16.00	20.00	26.00	31.00	13.00	21.00	28.00	36.00
Cash Equivalents	84.2%	0.00	0.00	1.00	5.00	3.00	8.00	14.00	20.00	19.00	4.00	11.00	9.00	6.00	12.00	16.00	21.00	17.00	9.00	16.00	24.00	34.00
Net PPE	-10.2%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-14.3%	18.00	21.00	37.00	39.00	45.00	42.00	43.00	40.00	30.00	25.00	26.00	24.00	23.00	24.00	24.00	24.00	26.00	5.00	5.00	5.00	7.00
Current Liabilities	-14.3%	17.00	20.00	35.00	37.00	42.00	39.00	36.00	33.00	29.00	24.00	25.00	22.00	18.00	19.00	19.00	19.00	9.00	5.00	5.00	5.00	7.00
Shareholder's Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	9.00	11.00	19.00	26.00	31.00
Retained Earnings	0.0%	-190	-190	-202	-195	-186	-180	-172	-165	-156	-135	-129	-123	-117	-111	-107	-100	-95.12	-87.53	-79.15	-71.09	-65.65
Additional Paid-In Capital	1.1%	171	169	169	166	153	153	153	152	152	122	121	114	106	105	105	104	104	98.00	98.00	97.00	97.00
Shares Outstanding	23.6%	45.00	36.00	36.00	27.00	18.00	18.00	18.00	12.00	11.00	11.00	10.00	10.00	9.00	9.00	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	12.00	-	-	-	73.00	-	-	-	50.00	-	-	-	59.00	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	77.4%	-983	-4,343	-4,002	-8,557	-4,265	-6,139	-10,166	-3,729	-8,593	-6,607	-4,007	-5,095	-5,584	-5,223	-4,574	3,670	3,870	-7,885	-7,814	-8,850	-4,714
Share Based Compensation	-4.8%	200	210	245	318	349	345	467	551	580	553	567	566	562	523	477	1,000	16.00	33.00	450	732	33.00
Cashflow From Investing	-	-	-	-	-49.00	-	-12.00	-21.00	43.00	-114	-124	-335	-334	-16.00	-4.00	-13.00	-121	-26.00	93.00	-120	-1,000	242
Cashflow From Financing	-67.0%	999	3,028	263	11,032	-554	-139	4,443	4,951	23,336	-149	6,582	7,949	-	715	14.00	18.00	4,967	-	8.00	10.00	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ARDS Income Statement

2023-09-30

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue:
Total revenue	$ 417	$ 399	$ 21,146	$ 1,878
Operating expenses:
Research and development	175	6,118	10,374	18,916
General and administrative	1,111	1,693	4,235	5,535
Total operating expenses	1,286	7,811	14,609	24,451
(Loss) income from operations	(869)	(7,412)	6,537	(22,573)
Other income (expense):
Interest income (expense), net	1	(27)	31	(267)
Other income	26	23	77	68
Change in fair value of note payable	759	(823)	(1,400)	(1,212)
Net income (loss)	$ (83)	$ (8,239)	$ 5,245	$ (23,984)
Earnings (net loss) per share:
Basic	$ 0.00	$ (0.47)	$ 0.15	$ (1.35)
Diluted	$ 0.00	$ (0.47)	$ 0.11	$ (1.35)
Weighted-average common shares outstanding used in computing net loss per share available to common stockholders:
Basic	37,428,943	17,701,592	35,562,129	17,701,592
Diluted	37,428,943	17,701,592	47,178,967	17,701,592
Other comprehensive (loss) income	$ 1,261		$ 2,736
Total comprehensive income (loss)	1,178	(8,239)	7,981	(23,984)
Grant [Member]
Revenue:
Total revenue	417	399	1,544	1,878
License [Member]
Revenue:
Total revenue			$ 19,602

ARDS Balance Sheet

2023-09-30

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35	$ 4,876
Restricted cash		183
Accounts receivable	417	1,000
Other receivables	100	240
Contract costs		1,986
Prepaid asset	3,558	3,341
Total current assets	4,110	11,626
Property and equipment, net	511	730
Right-of-use assets, net	1,073	1,417
Intangible assets, net	13	17
Restricted cash, non-current	500	500
Contract costs, non-current		78
Other assets	327	327
Total assets	6,534	14,695
Current liabilities:
Accounts payable	5,410	2,308
Accrued liabilities	7,691	9,564
Lease liabilities	576	538
Contract liabilities	380	20,173
Note payable		519
Note payable (at fair value)	3,410	3,781
Other liabilities	15	15
Total current liabilities	17,482	36,898
Contract liabilities, non-current		737
Lease liabilities, non-current	854	1,292
Total liabilities	18,336	38,927
Stockholders’ deficit:
Preferred stock (par value $0.0001; 60,000,000 shares authorized; zero shares issued and outstanding as of September 30, 2023 and December 31, 2022)
Common stock (par value $0.0001; 100,000,000 shares authorized; 44,574,021 and 27,033,532 shares issued and outstanding as of September 30, 2023 and December 31, 2022)	5	3
Additional paid-in capital	170,827	166,380
Accumulated other comprehensive income	7,787	5,051
Accumulated deficit	(190,421)	(195,666)
Total stockholders’ deficit	(11,802)	(24,232)
Total liabilities and stockholders’ deficit	$ 6,534	$ 14,695

About Aridis Pharmaceuticals Inc

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

CEO	Dr. Vu L. Truong Ph.D.
WEBSITE	aridispharma.com
INDUSTRY	Biotechnology
EMPLOYEES	37

Aridis Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Aridis Pharmaceuticals Inc? What does ARDS stand for in stocks?

ARDS is the stock ticker symbol of Aridis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aridis Pharmaceuticals Inc (ARDS)?

As of Fri May 17 2024, market cap of Aridis Pharmaceuticals Inc is 3.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ARDS stock?

You can check ARDS's fair value in chart for subscribers.

What is the fair value of ARDS stock?

You can check ARDS's fair value in chart for subscribers. The fair value of Aridis Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aridis Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ARDS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aridis Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ARDS is over valued or under valued. Whether Aridis Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Aridis Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARDS.

What is Aridis Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ARDS's PE ratio (Price to Earnings) is -2.73 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDS PE ratio will change depending on the future growth rate expectations of investors.